Cargando…

Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027

Clostridium difficile infection (CDI) is a leading cause of hospital-acquired diarrhea. In recent decades, the emergence of the “hypervirulent” BI/NAP1/027 strains of C. difficile significantly increased the morbidity and mortality of CDI. The pathogenesis of CDI is primarily mediated by the action...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Zeyu, Simeon, Rudo, Mitchell, Samuel B., Zhang, Junjie, Feng, Hanping, Chen, Zhilei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796971/
https://www.ncbi.nlm.nih.gov/pubmed/31578248
http://dx.doi.org/10.1128/mSphere.00596-19
_version_ 1783459723564023808
author Peng, Zeyu
Simeon, Rudo
Mitchell, Samuel B.
Zhang, Junjie
Feng, Hanping
Chen, Zhilei
author_facet Peng, Zeyu
Simeon, Rudo
Mitchell, Samuel B.
Zhang, Junjie
Feng, Hanping
Chen, Zhilei
author_sort Peng, Zeyu
collection PubMed
description Clostridium difficile infection (CDI) is a leading cause of hospital-acquired diarrhea. In recent decades, the emergence of the “hypervirulent” BI/NAP1/027 strains of C. difficile significantly increased the morbidity and mortality of CDI. The pathogenesis of CDI is primarily mediated by the action of two toxins, TcdA and TcdB, with TcdB being the major virulent factor in humans. In this report, we describe the engineering of a panel of designed ankyrin repeat proteins (DARPins) that potently neutralize TcdB from the BI/NAP1/027 strains (e.g., TcdB(UK1)). The most effective DARPin, D16, inhibits TcdB(UK1) with a 50% effective concentration (EC(50)) of 0.5 nM, which is >66-fold lower than that of the FDA-approved anti-TcdB antibody bezlotoxumab (EC(50), ∼33 nM). Competitive enzyme-linked immunosorbent assays (ELISAs) showed that D16 blocks interactions between TcdB and its receptor, chondroitin sulfate proteoglycan 4 (CSPG4). The dimeric DARPin U3D16, which pairs D16 with DARPin U3, a disrupter of the interaction of TcdB with Frizzled 1/2/7 receptor, exhibits 10-fold-to-20-fold-enhanced neutralization potency against TcdB from C. difficile strains VPI 10463 (laboratory strain) and M68 (CF/NAP9/017) but identical activity against TcdB(UK1) relative to D16. Subsequent ELISAs revealed that TcdB(UK1) did not significantly interact with Frizzled 1/2/7. Computation modeling revealed 4 key differences at the Frizzled 1/2/7 binding interface which are likely responsible for the significantly reduced binding affinity. IMPORTANCE We report the engineering and characterization of designed ankyrin proteins as potent neutralizers of TcdB toxin secreted by a hypervirulent ribotype 027 strain of Clostridium difficile. We further show that although TcdB toxins from both ribotype 027 and VPI 10461 interact efficiently with TcdB receptors CSPG4 and Pvrl3, TcdB(027) lacks significant ability to bind the only known physiologically relevant TcdB receptor, Frizzled 1/2/7.
format Online
Article
Text
id pubmed-6796971
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-67969712019-10-21 Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027 Peng, Zeyu Simeon, Rudo Mitchell, Samuel B. Zhang, Junjie Feng, Hanping Chen, Zhilei mSphere Research Article Clostridium difficile infection (CDI) is a leading cause of hospital-acquired diarrhea. In recent decades, the emergence of the “hypervirulent” BI/NAP1/027 strains of C. difficile significantly increased the morbidity and mortality of CDI. The pathogenesis of CDI is primarily mediated by the action of two toxins, TcdA and TcdB, with TcdB being the major virulent factor in humans. In this report, we describe the engineering of a panel of designed ankyrin repeat proteins (DARPins) that potently neutralize TcdB from the BI/NAP1/027 strains (e.g., TcdB(UK1)). The most effective DARPin, D16, inhibits TcdB(UK1) with a 50% effective concentration (EC(50)) of 0.5 nM, which is >66-fold lower than that of the FDA-approved anti-TcdB antibody bezlotoxumab (EC(50), ∼33 nM). Competitive enzyme-linked immunosorbent assays (ELISAs) showed that D16 blocks interactions between TcdB and its receptor, chondroitin sulfate proteoglycan 4 (CSPG4). The dimeric DARPin U3D16, which pairs D16 with DARPin U3, a disrupter of the interaction of TcdB with Frizzled 1/2/7 receptor, exhibits 10-fold-to-20-fold-enhanced neutralization potency against TcdB from C. difficile strains VPI 10463 (laboratory strain) and M68 (CF/NAP9/017) but identical activity against TcdB(UK1) relative to D16. Subsequent ELISAs revealed that TcdB(UK1) did not significantly interact with Frizzled 1/2/7. Computation modeling revealed 4 key differences at the Frizzled 1/2/7 binding interface which are likely responsible for the significantly reduced binding affinity. IMPORTANCE We report the engineering and characterization of designed ankyrin proteins as potent neutralizers of TcdB toxin secreted by a hypervirulent ribotype 027 strain of Clostridium difficile. We further show that although TcdB toxins from both ribotype 027 and VPI 10461 interact efficiently with TcdB receptors CSPG4 and Pvrl3, TcdB(027) lacks significant ability to bind the only known physiologically relevant TcdB receptor, Frizzled 1/2/7. American Society for Microbiology 2019-10-02 /pmc/articles/PMC6796971/ /pubmed/31578248 http://dx.doi.org/10.1128/mSphere.00596-19 Text en Copyright © 2019 Peng et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Peng, Zeyu
Simeon, Rudo
Mitchell, Samuel B.
Zhang, Junjie
Feng, Hanping
Chen, Zhilei
Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027
title Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027
title_full Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027
title_fullStr Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027
title_full_unstemmed Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027
title_short Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027
title_sort designed ankyrin repeat protein (darpin) neutralizers of tcdb from clostridium difficile ribotype 027
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796971/
https://www.ncbi.nlm.nih.gov/pubmed/31578248
http://dx.doi.org/10.1128/mSphere.00596-19
work_keys_str_mv AT pengzeyu designedankyrinrepeatproteindarpinneutralizersoftcdbfromclostridiumdifficileribotype027
AT simeonrudo designedankyrinrepeatproteindarpinneutralizersoftcdbfromclostridiumdifficileribotype027
AT mitchellsamuelb designedankyrinrepeatproteindarpinneutralizersoftcdbfromclostridiumdifficileribotype027
AT zhangjunjie designedankyrinrepeatproteindarpinneutralizersoftcdbfromclostridiumdifficileribotype027
AT fenghanping designedankyrinrepeatproteindarpinneutralizersoftcdbfromclostridiumdifficileribotype027
AT chenzhilei designedankyrinrepeatproteindarpinneutralizersoftcdbfromclostridiumdifficileribotype027